Dr. Sheila Wood’s microbiology experience has been shaped by feasibility projects in academic, government, private, and clinical lab environments and amplified by collaborations with competent scientists. Starting out with a Medical Technology degree, her first job was with the University of Virginia in the clinical microbiology lab. Her next experience at UVa was with the geographic medicine gr...
Dr. Sheila Wood’s microbiology experience has been shaped by feasibility projects in academic, government, private, and clinical lab environments and amplified by collaborations with competent scientists. Starting out with a Medical Technology degree, her first job was with the University of Virginia in the clinical microbiology lab. Her next experience at UVa was with the geographic medicine group and involved setting up a laboratory to serve patients in a small village in Brazil. Additionally, she helped develop laboratory media for Campylobacter, Entamoeba, and SXT susceptibility testing. UVa provided her with a good background in molecular microbiology during her time in basic science microbiology. Graduate school at VCU-MCV provided a PhD in Clinical Pathology with a specialty in microbiology. Graduate experiences included tissue culture, adherence assays, scanning electron microscopy, transmission electron microscopy, receptor characterization, and an appreciation for the pathogenic capabilities of Clostridium difficile. Post graduate work provided opportunities in industry (Becton Dickinson) and government laboratories. A fifteen year career period with the Department of Defense, yielded a substantial publication and patent roster. As part of this effort, projects with the University College Galway, Ireland and participated in NATO conferences in Italy provided a platform to present data on detection methods involving DNA hybridization, receptor adhesion binding, and antigen-antibody interactions. Teaching experiences include American University Medical School on St. Maartin, Rowan University in New Jersey and Clinical Laboratory Science School at St. Christopher’s Hospital for Children in Philadelphia. Most recently, after a return to the clinical microbiology laboratory in director positions, Dr. Wood has become involved in the identification of the agent that causes Lyme disease. Rarely has such a challenging and intriguing subject presented itself with such need. Clearly, the acquisition of many different acquired techniques proves to be useful in her present position. Her life in New Jersey revolves around her son and cat, as both contribute to her relaxation. Interests outside work include fly fishing, meditation, Reiki, energy healing, and metaphysics.
Development of molecular diagnostic testing methods
Dr. Xin Wang gained her MD at the age of 21 years from Hebei Medicine University in China. She specialized as neurologist to study cerebrovascular diseases. The project, stroke rehabilitation, awarded the First Prize of excellent paper at the Third Annual National Neurologic Rehabilitation meeting. After ten years clinical medicine practicing, including clinical research, she pursued a PhD in Medical Science from Institute on Aging and Adaptation, Graduate School of Medicine, Shinshu University, Japan. During the PhD course, she discovered an acute leukemia associated brain-specific gene and was the first one who studied its function at molecular & cellular biology level. The first postdoctoral training in NIH/NCI-Frederick in US, gave her an opportunity to complete a publication studying mouse models related to cardiovascular dysfunction that had been pointed as 'must reads' by Faculty1000. In Dental School & Medical School of University of Maryland, Baltimore, she studied Head & Neck cancer and Prostate cancer with Human specimen, Cancer cell lines and Animal models. Her summary of a project about the tumor microenvironment as primary author gained a Minority Scholar Award in AACR meeting. She is the CEO and CSO in biotechnology companies, ACURE TECHNOLOGY, Inc. that she is the founder, to develop and discover stem cell therapeutic products based on her extensive medical research experiences. She published more than 20 peer-reviewed papers in scientific journals.
Translational, Preventive, Clinical Research, To Develop and Discover New Therapeutic Approaches for Vascular Diseases, Cancer, Stem Cell Therapy and Anti-Tumor Microenvironment Strategy.
Mohammed Niazr Battikhi has done his Doctor of Microbiology/Microbial Taxonomy (1981), M.Phil degree (1979) in Microbial genetic from Leicester UK and his BSc degree in Biological Sciences from University of Jordan. Over the past thirty years, he worked in teaching and diagnostic laboratories and industry. Currenty, he is the consultant in Battikhi Central Laboratories, Jordan. He was assigned Chair of Medical Laboratory Science and Dietetics departments at Hashemite University and Professor of microbiology, Al-Israa Private University, Jordan. Dr Battikhi worked as consultant Microbiologist in dairy industry and a Microbiologist at Ministry of Health Central Laboratories. He has pioneered studies in disease infection, public health, epidemiology, oncology and environmental biological sludge treatment. He has many technical skills in medical laboratory testing, food and water analysis and quality control and extensive teaching, research and business skills; focused on the creation and development of communication skills driven new business opportunities, developing programs, new fields of study, builds relationships based on trust and performance; a team player at ease with colleagues; with international work experience.
Epidemiology and public health of infectious microorganism, Medical diagnosis of human Bacterial Infections and antibiotics resistant .Numerical and chemical Taxonomy, Biological Petroleum sludge treatment and oncology studying prostatic-specific antigen (PSA), a tumor marker for prostate cancer, prostatitis, chronic, benign prostatic hyperplasia (BHP)
Jason Paragas is the Deputy Director for the Office of Mission Innovation at Lawrence Livermore National Laboratory. The office focuses on the development of high risk/high impact programs. In this capacity, he leverages the laboratory’s unique national assets and complex workforce to solving the most challenging problems in biology facing National Security. He was previously the Senior Advisor (Science) to the Director, Joint Science and Technology Office Chemical Biological Defense, Defense Threat Reduction Agency, Department of Defense. During his tenure he led the development of the strategic architecture for the next generation of diagnostics, bio surveillance, and medical countermeasure science and technology investments.
Prior, he was the Associate Director for Science at the Integrated Research Facility, NIAID. While at NIAID, he led the development of a next generation translational medicine program for a new BSL-4 facility. By matrixing aspects of informatics, clinical medicine, industrial automation and contemporary virology research, an agile research capacity has been enabled to tackle the challenges of high consequence pathogens. The nascent program was able to engineer a novel Ebola virus vaccine, where he is a co‐inventor. He has served on multiple governments advisory groups including the Threat Reduction Advisory Committee.
Biocomputation; Biosurveillance; Drug discovery; High consequence pathogens; Medical imaging of infectious disease; Vaccines; Virology.
Abdel Omri obtained his PhD from Universite de Montreal in 1996. After completing postdoctoral fellowships at McGill University and the University of Toronto (1996-1998), he spent more than 2 years as Research associate at NRC (institute of biological sciences in Ottawa) from 1998 to 2000. He is currently Full Professor in the Department of Chemistry and Biochemistry with a cross appointment to the Department of Biology, the Biomolecular Sciences PhD Programme, School of Rural and Northern Health PhD Programme. His laboratory employs a multi-disciplinary approach to addressing the antimicrobial resistance to gram negative bacteria in cystic fibrosis patients and in medical devices implants. He is also involved in the education of undergraduate and graduate students through the co-ordination of several calendar courses in Biochemistry, Pharmacology, Toxicology and Pharmaceutical technology. In addition to research, he is actively involved in the research training of both undergraduate and graduate students. He served in administrative capacities in several international scientific societies. He has published over 50 peer-reviewed research articles over his career on various aspects of drug delivery and targeting in addition to several published book chapters and books (2). He has served on a number of Editorial Boards and Granting Agencies in Canada and abroad and has 2 patents.
Lipid-Based Drug and Vaccine Delivery Systems, Antimicrobial Resistance to Gram Negative Bacteria, Biofilms, Quorum Sensing, Pseudomonas aeruginosa, B. cenecepacia, Biomaterial related infection, Medical implantsinfection, Antibiotic resistance, Aminoglycosies, Macrolides
Akbar S. Khan is an interagency lead, Senior Microbiologist, Program Manager and Subject Matter Expert (SME) for Chemical & Biological Directorate Basic Sciences Directorate at Defense Threat Reduction Agency. He also serves as an Agency lead to National Nanotechnology Initiative (NNI) where he coordinates DTRA-CB Nanotechnology activities with NNI does technology watch for CB and run a technology watch seminar series program and coordinating officer to OSD for Dual Use Research of Concern (DURC). Prior to this position, he served as a program manager for Chemical & Biological Directorate Basic/Medical Sciences programs where he managed therapeutics and also managed Transformational Medical Transition Initiative (TMTI) portfolios. He joined DTRA in 2004 and received Director’s annual team award for excellence in program management and execution 2006, 2009 and 2011. He is certified at Level III in S&T management and acquisition and also Defense Acquisition Corp Certified. He also served at Office of Secretary of Defense for DTRA to provide managerial and leadership support to manage the Combined Federal Campaign for Department of Defense from 2006 till 2008. He joined DTRA in 2004 from US Army Edgewood Chemical Biological Center (ECBC) at Aberdeen Proving Grounds where he served as Research Biologist and Program Manager from 1999 till 2004. During his tenure at ECBC, he worked with a variety of projects which included Toxicogenomics, Biotechnology, Threat Agent Science, Genomics and Proteomics of Infectious Disease Agents, Agent fate of Infectious Disease Agents, Biosensors and Computational Biology. From ECBC, he helped in cooperative threat reduction (CTR) program for DTRA as a subject matter expert. He also managed MASINT programs for Air Force for developing Taqman assays using genetic material for detection of infectious biological threat agents and developing a miniaturized Surface Plasmon Biosensor for detection of these agents in collaboration with University of Washington at Seattle. Before joining ECBC, He served at United States Army Medical Research Institute of Infectious disease from 1998 till 1999 as a Scientist where he worked with a team of Scientists to design and develop recombinant vaccines against Staphylococcal Enterotoxins. He received his doctorate degree from University of Oklahoma, Norman, Oklahoma in 1989, where he studied DNA version of tRNA and published the results in Science (1988). He completed his post-graduate training from University of Colorado School of Medicine with a post-doctoral fellowship from Alcohol and Drug abuse program at NIH. During this time, He collaborated with Dr. Craig Venter and did some earlier genomics work and published the results in Nature Genetics (1992). From 1992 till 1998, He served at scientist level positions at Noble Foundation for Biomedical Research in Oklahoma where he studied Cancer Genetics and at University of Oklahoma, where he was instrumental in sequencing and analyzing human chromosome 22 with a team of international investigators and published the results in Nature (1999 & 2001). He also served as an adjunct professor at University Maryland School of Medicine from 2002-04 and University of Colorado School of Medicine from 1990-92. His other awards include the DTRA Director’s annual team award for performance excellence in program management and science advisory, Moreland Loaned Executive Awards from Office of Secretary of Defense in 2007 & 2008, Office of the Secretary of Defense, Award for Excellence in 2007 & 2008, DTRA Director’s Annual Team Award for excellence in program management and execution in 2006 & 2009, Research and Development Achievement Award from Department of Army in 2002, Young Scientist of Year award from Baltimore Federal Executive Board in 2001, Excellence in Research award from Army Scientific Board in 2000 and gold medals from Aligarh University, India for being ranked 1st in B.Sc and M.Sc in 1977 and 1979. He published over 100 manuscripts, six patents, co-edited two books, several book articles and given over 100 presentations to national and international audience. He also served as technical liaison from ECBC for Defense Science Board in 2000, DARPA computational biology Biospice program from 2004 till 2006 and Bio-threat panel organized by NSF and Intelligence Agencies for Presidential panel in 2003 and serves as a scientific government liaison at National Academy of Sciences in Emerging Sciences for Environmental Protection panel. In past, he served as a consultant with a variety of private Genomics & Biotechnology companies.
Genomics and Bioinformatics, Pathogen Detection, New Emerging Pathogens
Frans J de Bruijn started his scientific career at the Cold Spring Harbor Laboratory in New York, USA, where he worked on Bacteriophage Mu and transposable elements in bacteria with the late Dr. Ahmad Bukhari. He then moved to Harvard University in Cambridge USA to carry out his PhD research on the regulation of nitrogen fixation and assimilation genes of Klebsiella pneumonia and Sinorhizobium meliloti with Professor Fred Ausubel. He briefly continued on as postdoctoral fellow at the Department of Molecular Biology at the Massachusetts General Hospital with Dr. Ausubel working on glutamine synthesis genes in Rhizobiacea, before leaving for the Max Planck Institute for Plant Breeding in Cologne, FRG with an EMBO Postdoctoral Fellowship to work with the late Prof. Jeff Schell on plant microbe interactions. After two years he became Group leader with a team of 10-15 members working on various aspects of plant-microbe interactions, especially with the tropical stem-nodulated legume Sesbania rostrata, which he helped, pioneer as a model legume of study. After Four years he became Assistant to the Director Dr. Jeff Schell, responsible for many organizational and administrative matters. After seven years, he accepted the offer of an Assistant Professor at Michigan State University, East Lansing USA and quickly climbed to the post of Full Professor continuing his work on plant-microbe interactions, Environmental Control of Gene Expression in Sinorhizobium meliloti using the Tn5luxAB reporter transposon and bacterial phylogeny using rep-PCR genomic fingerprinting , which he co-developed with his collegue Prof. James Lupski at Baylor College of Medicine in Houston USA, in addition he became Director of the Genetics Graduate Program at MSU, with 50 PhD and 60 affiliated Faculty members. While at MSU he was also appointed at the NSF Center for Microbial Ecology led by Prof. James Tiedje and included various Molecular Microbial Ecology research topics in his program. Subsequently he co-edited the popular “Molecular Microbial Ecology Manual”. In 2000 he received an offer to be the Director of the Laboratory for Plant-Microbe Interaction, a mixed INRA/ CNRS research facility with about 100 scientists and support staff in Toulouse, France. He served as Director for two years after returning to the laboratory as Director of Recherche DR1, where he now continues his research work and took five years off to edit the “Handbooks of Molecular Microbial Ecology and Metagenomics”, the “Molecular Microbial Ecology of the Rhizosphere” and”Biological Nitrogen Fixation”.
Plant-Microbe Interactions, Molecular Microbial Ecology, Biological Nitrogen Fixation, and Microbial Control of Gene Expression
Cheorl-Ho Kim is currently the Professor of Department of Biological Science, College of Science, Sungkyunkwan University, Suwon City, Korea. He gained his PhD in 1990 from Laboratory of Biological Chemistry, Department of Agricultural Chemistry, The University of Tokyo, Tokyo, Japan. He was Lecturer at Tokyo College of Pharmaco and Medico-Technology, Tokyo, Japan during 1987-1989 and Senior Researcher at Genetic Engineering Center, KIST, Korea, Genome Program Head at Korea Research Institute of Bioscience and Biotechnology from 1990-1996. From 1996-2006, he was the Assistant Professor, Associate Professor, Professor and Chairman of Department of Biochemistry and Molecular Biology, College of Oriental Medicine, Dongguk University, Gyungju, Korea. He was the Professor of Department of Biological Sciences, Sungkyunkwan University, Suwon, Korea in 2006 and Visiting Professor of The Institute of Glycoscience, Tokai University, Kanagawa, Japan in 2010. He has published over 300 peer-reviewed articles.
Roger Dabbah, PhD is the Principal Consultant at Tri-Intersect Solutions which provides consulting, training in R & D and QA in the Pharmaceutical, Biotechnology and Medical device industries with specialization in Microbiology testing, Sterilization systems, Sterility assurance and Management of laboratories. He also serves as an adjunct Associate Professor at the University of Maryland, University College teaching courses in technology management including Project management, Risk management in projects and at Johns Hopkins University, Whiting School of Engineering. Prior to his current positions he served as Director of the Complex Actives Division of the Drug Standards Department at the US Pharmacopeia. Before joining the US Pharmacopeia he was a Corporate Director of the Division of Microbiology, Sterilization and Immunology for Baxter Healthcare, Manager of R & D Administration for the Nutritional Division of Abbott Laboratories and Manager of the Biological and Information Sciences in technical services. He has published extensively papers and articles on Microbiology, Biotech, and Management. He was collaborated in a number of technical books by contributing a number of chapters. He is also the author of two books, one on Project Management and one on R & D Management in the Pharmaceutical industry. He is also on the Editorial Board of Pharmaceutical Technology and BioProcess International and on the Board of Director of the PDA Foundation for Pharmaceutical Sciences.
Sterilization modes, Rapid Microbiological methods of testing
Hazem Aqel is a Professor in Medical Microbiology at King Saud Bin Abdulaziz University for Health Sciences. He obtained his B.Sc. degree in Medical Laboratory Technology from Kuwait University, Kuwait, his M.Sc. degree in General and Medical Microbiology from University College London, UK and his Ph.D. in Microbiology from Birmingham University, UK. He has pioneered structural studies of isolation and characterization of Thermophilic Bacteria and Bacteriophages, Bacterial enzymatic activities, Antimicrobial plant extractions and understanding Pathogenicity, Latency and Reactivation of Viruses. His current researches are in viral infection and antibiotics resistance.
Pathogenicity, Latency and Reactivation of viruses in their host to produce Vaccine, Bacterial cells response to the environment by altering which Protein they Synthesize, Bacterial detection and response to Stressful Conditions.
Volker Patzel, chemist, received his PhD. in 1998 from the Ruprecht-Karls-University in Heidelberg and in 2002 his MBA from the Steinbeis University in Berlin. Worked until 2000 as a postdoc at the German Cancer Research Centre in Heidelberg and then till 2009 as research group leader at the Max Planck Institute for Infection Biology in Berlin. Since 2009 he holds a dual appointment as Assistant Professor at the National University of Singapore and Assistant Director of Research at the University of Cambridge. Since 2004, he is the Founder and Director of the Steinbeis Transfer Centre for Nucleic Acids Design.
Design and delivery of ribonucleic acids for enhancement; Inhibition or repair of gene expression towards diagnosis and treatment of human diseases; Viral pathogens such as HIV-1, HPV-16, HBV and cancer
Adnan S Jaran is an Associate professor of Microbiology and Molecular Biology at Al Al-Bayt University, Mafraq Jordan. He has obtained his BSc. In Medical Technology from Yarmouk University, Jordan and MSc. In Microbiology and Immunology from the University of Manchester, United Kingdom and PhD. in Microbiology and Molecular biology from the University of Manchester, United Kingdom in 1995. He worked as research scientist at the Royal infirmary hospital in Manchester for two years, then moved to Jordan and worked as a lecturer and researcher at the Jordan University for Science and Technology for one year before moving to Al Al-Bayt University. He spent four years teaching and researching at the college of Medicine /Al Imam Mohammed ibn Saud Islamic University in Saudi Arabia (2010 -2014).
In the past 17 years, he has engaged in research in the fields of Plasmid isolation, antibiotic resistance and isolation and characterization of genes conferring resistance in both gram positive and gram negative bacteria and Antioxidant and Antimicrobial effects of different extracts of medicinal and traditional local and regional plants.
Isolation and molecular characterization of antibiotic resistance genes, Antimicrobial and antioxidant effect of plant extracts. Diagnosis of pathogenic bacteria, parasites, fungi and Viruses.
The Vaccine & Gene Therapy Institute of Florida
Ted Ross PhD, is a program director and a principal investigator at the Vaccine & Gene Therapy Institute of Florida (VGTI Florida) was one of the country’s foremost influenza researchers. He explores new vaccine technologies intended to protect against all strains of seasonal influenza -an endeavor that could potentially eliminate the need for seasonal flu shots. Today’s flu vaccines are a mixture of inactive influenza viruses. He, however, is taking a novel approach by examining the use of a synthetic vaccine created from genetic sequences of many different flu viruses. He previously used this method to produce a vaccine against the H5N1 virus commonly known as the bird flu. The vaccine, well-tolerated in pre-clinical trials, successfully protects against known strains of bird flu. He and his VGTI Florida colleagues are applying similar strategies to fight other serious viruses such as West Nile Virus, Dengue and HIV Type 1 (HIV-1). Prior to joining VGTI Florida, he was an Associate Professor, University of Pittsburgh School of Medicine, where he served in the Microbiology and Molecular Genetics department and was a full member of the Center for Vaccine research. Before that, he was an Assistant Professor in the Department of Microbiology and Immunology at East Carolina University, School of Medicine in North Carolina. He has co-authored numerous scientific articles published in journals such as Nature Immunology, The Journal of Virology, Journal of Infectious Disease, Vaccine and The Proceedings of the National Academy of Sciences. He is a member of the American Society for Virology, American Society of Microbiology, Sigma Xi, International Society of Vaccines and others. He holds B.S. and M.S. degrees from the University of Arkansas in Zoology and Microbiology, respectively. He earned his PhD from Vanderbilt University in Microbiology & Immunology. Additionally, he was a Postdoctoral Fellow in HIV Research at Duke University and a Senior Research Associate in HIV Vaccine Research at Emory University.
Development of Broadly Reactive Vaccines using computationally optimized broadly reactive antigen (COBRA) modeling. Influenza, HIV, Dengue; Modeling Immunity to Biodefense agents and influenza; Influenza VLP-based vaccines for seasonal and pandemic influenza; Pathogenicity/Genomic Modeling of influenza infection in adult and elderly ferrets, and humans; Evaluation of human clinical samples following influenza vaccination; Development of tetravalent Dengue VLP-based vaccines; Development of VLPs for RVFV and CCHFV; Multiclade Consensus Env VLP AIDS vaccine; Using Consensus Env Sequences to broaden immunity; Using C3d adjuvants in a DNA vaccine to enhance the immunogenicity to HIV/SIV, RVFV, Dengue, West Nile, Chikungunya virus envelopes; Development and testing pandemic H5N1, H1N1, H7N9 subtypes
Asem Shehabiobtained his Doctor of Medical Sciences/ Medical Microbiology from University of Kiel, Germany (1972). Over the past 40 he has worked in teaching, diagnostics hospital laboratories and research in medical microbiology. He is currently Prof. of Medical Microbiology & Consultant in Diagnostic Microbiology, Faculty of Medicine and The University of Jordan. He is founder and Vice President of Arab Alliance for Prudent Use of Antimicrobial Agents, Cairo, Egypt (2004-2013) and Editor-in-Chief of The International Arabic Journal of Antimicrobial Agents (2011-present). He ison the editorial board of many international medical and scientific journals.He was WHO free consultant (1985-2009) on various medical microbiological issues. He was honored 6 times with researchscholarships in USA, Germany, England and Sweden. He has published 78 research papers in peer-reviewed journals, 2 Microbiology Books & more than 300 articles and studies in Arabic and English covered most important aspects of medical microbiology and human infectious diseases.
Medicaldiagnosis of human pathogenic bacteria,virus and fungi; Epidemiology of infectious agents and antimicrobial resistance; Detection of virulence factors & toxins of bacteria & Fungi by molecular techniques
Tim Sandle is a chartered biologist and holds a first class honours degree in Applied Biology Masters degree in education and has a doctorate from Keele University. He has over twenty-five years experience of microbiological research and biopharmaceutical processing. This includes experience of designing, validating and operating a range of microbiological tests including sterility testing, bacterial endotoxin testing, bioburden and microbial enumeration, environmental monitoring, particle counting and water testing. In addition, he is experienced in pharmaceutical microbiological risk assessment and investigation. He is a tutor with the School of Pharmacy and Pharmaceutical Sciences, University of Manchester for the university’s pharmaceutical microbiology MSc course. In addition, he serves on several national and international committees relating to pharmaceutical microbiology and cleanroom contamination control (including the ISO cleanroom standards). He is a committee member of the Pharmaceutical Microbiology Interest Group (Pharmig); serves on the National Blood Service advisory cleaning and disinfection committee; and is a member of several editorials boards for scientific journals. He has acted as a consultant, expert witness and technical advisor to sterile and non-sterile manufacturing facilities, microbiology laboratories, the medical device industry and hospitals. He has also undertaken several technical writing and review projects. He has written over two hundred book chapters, peer reviewed papers and technical articles relating to microbiology. This includes editing the book "The CDC Handbook: A Guide to Cleaning and Disinfecting Cleanrooms"; and co-editing the comprehensive books "Microbiology and Sterility Assurance in Pharmaceuticals and Medical Devices" and "Cleanroom Management in Pharmaceuticals and Healthcare". He has also delivered papers to over fifty international conferences.
Igor M Belyakov is a Faculty Member in the Michigan Nanotechnology Institute for Medicine and
Biological Sciences (University of Michigan, USA). After receiving his M.D. with honors from the Vladikavkaz's School of Medicine (Russia) in 1983, he obtained his Ph.D. in Immunology from the Chelyabinsk Medical School (Russia) and went on to serve as Chair of the Department of Microbiology and Immunology in the Vladikavkaz's School of Medicine in 1988. He was awarded a Doctor of Science degree in immunology and medicine in 1993 and started a fellowship at the University of Alabama at Birmingham (USA), going on to join the National Cancer Institute (NIH) in 1996. He has authored over 100 articles in peer-reviewed journals. These papers represent advances in our understanding of the role of mucosal immunity in vaccine development. His earlier work demonstrated a fundamental dichotomy between the systemic immune system and the mucosal immune system in eliciting activated CD8+CTL. These findings have contributed to the field of Vaccinology including HIV vaccine design and development. He went on to pioneer the development of a multicomponent HIV/SIV vaccine leading to the first mucosally delivered vaccine which showed efficacy against mucosal challenge with pathogenic HIV virus. He has made significant contributions to elucidating new principles governing T-cell activation, regulation and effector function in gastrointestinal mucosa. He uses these new principles to develop more effective mucosal vaccines and immunotherapy strategies for pathogens causing infectious diseases. He was elected to the Russian Academy of Natural Sciences in 2009.
Mucosal immunology, Immunology of virus-host interactions at the mucosal interface, Emerging infectious diseases and using new nanotechnologies to the prevention and treatment of infectious diseases, Basic research in immunology with the application to the pathogenesis of infectious diseases and vaccines.
Keith Warriner is currently the President of the Ontario Food Protection Association and the Professor of the Department of Food Science at University of Guelph, Canada. He received his BSc degree in Food Science from the University of Nottingham, UK and PhD in Microbial Physiology from the University College of Wales Aberystwyth, UK. He later worked on biosensors within the University of Manchester, UK and subsequently returned to the University of Nottingham to become a Research Fellow in Food Microbiology. He joined the Faculty of the University of Guelph in 2002.
During the last fifteen years in the field of microbiology and food safety research, he had published more than 100 papers, Book Chapters, Patents and Conference abstracts. He has given numerous media interviews on food safety issues and appeared on CBC Marketplace to highlight sanitation issues with hotel room. His research areas encompasses on the Development of Decontamination Technologies, Biosensors for Biohazard Detection and more fundamental research on the interaction of Human Pathogens with Plants.
Food microbiology, Diagnostics
Victor Babes University of Medicine and Pharmacy
Tudor Rares Olariu is Visiting Professor at Stanford University, California, USA and Professor of Parasitology and Chief of the Discipline at Victor Babes University of Medicine and Pharmacy in Timisoara, Romania. He is also the Chief of Clinical Laboratory at the Municipal Clinical Hospital in Timisoara, Romania and PhD coordinator in Parasitology. He received his Medical Doctor degree from Iuliu Hatieganu University, Romania and his PhD. in Parasitology from Victor Babes University, Romania.
Parasitology with a focus on toxoplasmosis and intestinal parasitic infections
Dr. Skip Seward owns Seward Global Consulting. His previous industry and trade association experience includes, ConAgra Foods (Vice President-Global Food Safety), the American Meat Institute (VP- Regulatory Affairs), McDonald’s Corporation (Director-Global Food Safety), Oscar Mayer, General Foods, Stauffer Chemical Company and the Del Monte Corporation. He received PhD in Food Microbiology from the University of Wisconsin in 1982 and his BS and MS degrees in Microbiology from Colorado State University and Oregon State University, respectively. He is currently serving, on the National Advisory Committee on Microbiological Criteria for Foods, the Beef Industry Food Safety Council, the U.S. BSE Emergency Response task force, the FSIS Food Defense task force, and industry task forces to define sanitary design principles, nut safety programs, and food lot definition, control and justification. He recently participated in the development of FDA Guidance Documents for implementation of the Food Safety Modernization Act. He has published in professional journals and written several chapters on food service HACCP, food safety, and performance standards.
Willem JG Melchers obtained his Master degree in Molecular Biology at the University of Nijmegen in 1986. He obtained his PhD degree in 1989 at the Free University of Amsterdam on the relationship between human papillomavirus infection and the development of cervical cancer. He has been working at the Radboud university medical center, department of Medical Microbiology since 1989. He is associated professor in Molecular Microbiology. He is head of the clinical laboratory of Medical Microbiology (Chef de Laboratoire) and heading the section of Molecular Diagnostics. The developments in Molecular Diagnostics, have grown explosively in the last decades. The impact of molecular diagnosis of infectious diseases is both related to a laboratory change from artisanal to technology based diagnostics and to patient management (monitoring, therapy etc). The area of this part of his work involves technology development and clinical application for the benefit of public health. Research interests are in molecular microbiology, with a specific focus on the molecular mechanisms of fungal resistance. Invasive aspergillosis (IA) is a rapidly fatal disease in immunocompromised patients with a mortality rate as high as 85%. Prognosis is directly associated with timely diagnosis and prompt appropriate antifungal therapy. Triazoles are now used for primary therapy in many centers around the world. We have observed a rapid emergence of multiple-triazole-resistance (MTR) in Aspergillus fumigates.He is also interested in the relationship between HPV infections and the development of cervical cancer. Cervical cancer accounts for 10% of all cancer related deaths in women. Each year 470,000 women are worldwide diagnosed with invasive cervical cancer, and 230,000 women die because of this disease. Studies have clearly demonstrated that infection by human papillomavirus (HPV) is a necessary cause for the development of cervical cancer. The infection, however, is widespread and current studies of him are focusing on the secondary factors related to progression from subclinical infection to invasive cervical cancer. He published over 300 peer-reviewed papers on these subjects.
Molecular diagnosis of infectious diseases; HPV and malignancies (cervical and oral); Aspergillus resistance
Dr. Stefan Denev has more than 35 years of experience in higher education, research, transfer of knowledge, scientific expertise, technology transfer and new product development. Currently, he is Professor of Microbiology and Chair of Department of Biochemistry and Microbiology at Trakia University, Bulgaria. He receivedhis M.Sc., Ph.D. and D.Sc. degrees in the field of Microbiology and Nutritional Biotechnology. He was awarded with Post-Doctoral Research Fellowships for completing post-doctoral studies at University of Groningen (The Netherlands), as well as at National Institute of Animal Industry, Tsukuba (Japan) (1996-1998) and etc. He has been a Visiting Professor/Researcher/Scientist at several prestigious universities as Groningen, Utrecht and Wageningen Universities (The Netherlands); University of Johannesburg and Rhodes University (S. Africa), as well as a Guest Professor at many other universities and research institutions in Europe, USA, Africa and Asia. He has served as Chairman/Session Chair for many Congresses, Conferences, Symposiums in the field of Microbiology and Biotechnology; Food Science and Technology; Food Safety and Food Protection; Mycology and Mycotoxicology; Veterinary and Animal Sciences. Stefan Denev has published above 150 peer-reviewed papers; 20 Books and Book Chapters; 2 Patents; 5 Innovations and Implementations; 65 Invited Papers, Posters and Abstracts in the above research areas. He supervised more than 30 graduate students and post docs, and received many honours and prestigious research awards. Currently, he is a member of several Societies and Scientific Expert Committees. He is also Editor, Editorial and Advisory Board member, and Reviewer on a number of international peer-reviewed journals.
Applied Microbiology and Biotechnology; Food Microbiology, Food Quality and Safety; Intestinal Microbiology; Lactic Acid Bacteria; Functional Foods and Ingredients (Prebiotics, Probiotics, Synbiotics, Phytobiotics); Mycology and Mycotoxicology; Nutrition and Health; Bio-Nanotechnology
Antonio Marcilla obtained his PhD from University of Valenciain 1991. He was awarded NATO and NIH Fogarty International Center fellowships for completing a post-doctoral stay at Laboratory of Cellular Development and Oncology, NIDR-NIH, Bethesda, MD, USA (1993-1995). He was Associate researcher at Cytological Research Institute, Valencia, Spain, (1995-1996) and University of Valencia(1996-1998). He was Assistant Professor of Parasitology (1998-2002), From 2002 he is Associate Professor at the Departmentof Cell BiologyParasitology, Faculty of Pharmacy, University of Valencia, where he teaches Molecular Parasitology and Immunology. He has been focused on the study of host-parasite interactions at molecular level, mainly using “–omics” technology (genomics, transcriptomics and proteomics). His current research interests deal with the study of parasitic extracellular vesicles (exosomes) as a potential control tools for parasitic and other diseases. He published over 70 peer-reviewed research articles on Microbiology, Parasitology and Tropical Medicine as well as book chapters.
He has served as reviewer for Spanish and International Research Agencies, as well as for several International Scientific Journals. He is currently member of five Editorial Boards and five Scientific Societies.
Mukesh Kumar conducts research on various emerging pathogens including West Nile virus (WNV) and Hantaviruses using cell culture models, Mouse models and Biological specimens. His work encompasses both basic researches in trying to understand more thoroughly how these agents cause disease and how the Human immune system responds to these infections, and more directed research in developing and evaluating vaccines and other tools to prevent infection by these agents. He investigates the efficacy of anti- inflammatory drugs as a potential therapeutic target to manage WNV encephalitis. Another area of his research is to understand the mechanisms underlying differential pathogenesis of lethal and non-lethal WNV strains. His work also involves developing novel small animal models to study infectious pathogens. He work for the first time evaluated the effect of diabetes mellitus on the susceptibility and immune response to WNV infection, which is very significant for the development of effective therapeutics not only for management of WNV in diabetics but also other infections in diabetics as well. He is collaborating internationally and has contributed to the development of a rapid, sensitive luminex-based test for the diagnosis of WNV, new anti-WNV drugs and potential biomarkers to predict severe hantavirus-associated diseases. He is a member of several national and international societies such as American Society for Virology, American Society for Microbiology, Society for Neuroscience, Federation of Clinical Immunology Societies and American Association of Immunologists etc. He is currently serving as the secretary of American Society for Microbiology, Hawaii Branch. He has also served as Editorial board member and reviewer on a number of peer-reviewed journals.
Infectious diseases, Viral immunopathogenesis and Virus-host interactions
Chandra Mittal is the Professor of Biotechnology and Biological Sciences at Houston Community College, Houston. He has served HCC since 2002. Prior to this he was President and CEO of Herichson Biotech, Inc, Texas; Senior Research Pharmacologist at Texas Southern University; Director of Biomedical Research at Escorts Heart Institute, Delhi; Assistant Professor of Pharmacology at University of Illinois College of Medicine and Instructor in Pharmacology at University of Virginia. He completed his M.S. (Biochemistry) at Lucknow University, PhD (Biochem, Pharmacology) at All-India Institute of Medical Sciences (AIIMS), New Delhi and Fellowship (Pharmacology) at University of Virginia. He is also an elected fellow of American College of Clinical Pharmacology. His field of research since 1969 has been cyclic AMP, cyclic GMP signaling system. His most notable scientific contribution has been co-discovery of the Nitric Oxide-Cyclic GMP Signaling system with Dr. Ferid Murad who won the 1998 Nobel Prize in Medicine or Physiology. His work on novel regulation of cyclic GMP metabolism and Nitric Oxide synthesis is published in peer-reviewed international journals. He has also served on expert panels of various national research sponsors like NIH and NSF as well as review boards of biomedical research journals. Besides academic engagement, he is also actively involved as consultant/adviser with medical industry in the area of diagnostics and therapeutics.
Cellular signaling mechanisms; Hormone action; Vasodilatation; Molecular mechanisms of hypertension; Novel therapeutic modalities for erectile dysfunction (ED)
Wadud Bhuiya is a senior scientist in MOgene, USA. His current project focused on microbial production of biofuel from natural gas. He received his BSc ad MSc in Microbiology from Dhaka University, Bangladesh and PhD in Protein Science from Tokushima University, Japan in 2002. He worked on protein crystallography in Wake-Forest University and Drexel University College of Medicine and published papers and book chapter. He worked in structure-guided protein engineering in Brookhaven National Laboratory (2007-2010) and Conagen (2011-2013) for production of biofuel from renewable biomass. He has solved 5 protein structures, published 10 peer-reviewed papers and has 3 patents. He has trained undergraduate, graduate students, and research associate for molecular cloning, protein expression, protein purification, protein characterization, crystallization and 3D-structure determination. He supervised junior scientists various software for protein modeling, docking and directed evolution to improve protein traits.
Prof. Yehia S A Mohamed is presently working as Assistant Professor, Department of Microbiology, Dammam University, KSA. Prior to Dammam University post, He served as a lecturer of Microbiology and Immunology, Al-Azhar University of Cairo, Egypt. This was directly after being awarded by his PhD in Infection, Immunity and Inflammation in November 2011, from Leicester University, UK. After finishing his undergraduate study of pharmaceutical Sciences in Al-Azhar University of Cairo with the grade of honour, he started his postgraduate study and was awarded his PhD in Dept of infection, Immunity and Inflammation, College of Medicine, Biological Sciences and Psychology, Leicester University, UK, in Nov 2011. He holds memberships in many prestigious societies like Saudi Society of Infectious Diseases and Microbiology (2013- present), European Association of Cancer Research (2009 – present); British Society of Immunology (2008 – present) Egyptian Pharmacy Syndicate (2000-present); His Research Interest Include; Investigation advances of malignant diseases management via modification of the host immune mechanisms, especially cellular immunotherapy and cancer vaccines. Immune response and resistance patterns of Mtb. He also serves as Member of review panel of“Africa Development and Resources Research Institute Journal”; Reviewer in OMIC publishing group; Reviewer in International Journal of Vaccines and Immunization; Assistant editor in “ Bio-accent group”, MOJ ImmunologyJournals.
Investigation advances of malignant diseases management via modification of the host immune mechanisms; Especially cellular immunotherapy and cancer vaccines; Immune response and resistance patterns of Mtb.
Dr. Wilmore Webley earned his PhD in microbiology with expertise in immunology, pathogenic bacteriology, and host-pathogen interactions at the University of Massachusetts in 2003. He is currently a tenured Associate Professor of microbiology at the University of Massachusetts Amherst. His research has focused on Chlamydia vaccine development and the role of pathogenic microbes in asthma initiation and exacerbation. The Webley Lab is using immunoinformatics and the gas vesicle nanoparticles of Halobacteria as a platform for multi-subunit antigen display and has confirmed that this system is a potentially effective display and delivery platform for antigens of chlamydial vaccine interest. His laboratory was the first to culture Chlamydia from bronchoalveolar lavage samples taken from pediatric patients with chronic, severe asthma and has since shown that early life chlamydial infection increases the risk for asthma onset. His recent work has demonstrated the efficacy of antibiotics in treating a subset of severe asthmatics. His work has been published in reputable international journals and has made significant contributions to the field of microbiology, vaccinology, allergy and immunology. He is a member of the International Society for Vaccines, American Society for Microbiology, the Chlamydia Basic Research, Society and Sigma XI - The Scientific Research Society.
Role of Chlamydia in Asthma Pathogenesis; Development of an Efficacious Chlamydia Vaccine; Design of a point-of-care diagnostic test for Chlamydiainfection in farm animals
Dr. Xiaofa Qin obtained his MD, PhD in Beijing Medial University, Beijing, China then became a lecturer and associate professor there. Later, he came to the United States and engaged in medical research as a postdoc, research instructor and assistant professor consecutively in Louisiana State University (LSU) Medical Center in Shreveport, University of Cincinnati college of Medicine, and University of Medicine and Dentistry of New Jersey (UMDNJ, now merged with Rutgers)-New Jersey Medical School. He had a great interest in the possible causative role of dietary chemicals such as the widely used artificial sweeteners saccharin and sucralose in inflammatory bowel disease (IBD, including ulcerative colitis and Crohn’s disease), as the result of inhibition on gut bacteria, impaired inactivation of digestive proteases, damage of the mucus layer and underlying gut tissue, and increased infiltration of bacterial and dietary components from gut lumen. Recently, he founded GI BiopharmaIncto develop some new treatments for IBD and other diseases.
The association among dietary chemical; Gut microbiota; Diseases like inflammatory bowel disease (ulcerative colitis and Crohn’s disease)
Felix J Tapia is an active researcher in the study of local immune responses in cutaneous and visceral leishmaniasis. His work demonstrated differences within lesions of patients with localized cutaneous-, mucocutaneous and diffuse leishmaniasis, regarding lymphocyte activation and dendritic cells (DCs). These studies established the epidermis as an important regulatory site in leishmaniasis, demonstrating the involvement of DCs. He also demonstrated the Th1/Th2 dichotomy in human leishmaniasis and noted that the disease is caused by an exacerbated immune response rather than a reaction against the parasite. At present, he is studying the participation of DCs in the transition between innate and acquired immunity, and the regulatory mechanisms of inflammation stress mouse models of cutaneous leishmaniasis.
Dendritic cells; Immunoparasitology; Immunoregulation; Immune response; Innate and Adaptive immune responses; Leishmania; Leishmaniasis; T cells
Louboutin is a Neurologist interested in gene therapy/cell therapy as well as in neurovirology. He recently focused his work on the role of oxidative stress in the neuropathogenesis of HIV-1. By developing different animal models of HIV-1 Associated Neurocognitive Disorder (HAND), he studied the deleterious effects of HIV-1 envelope glycoprotein gp120 and non-structural protein Tat in the brain (apoptosis, oxidative stress, neuroinflammation, abnormalities of the blood-brain barrier, upregulation of MMPs). Gene delivery of antioxidant enzymes SOD1 and GPx1 in different situations (intracerebral, intrathecal, intravenous), and assessed in different experimental settings, protected neurons against gp120- and Tat-induced apoptosis and other harmful effects. Gene delivery to the spinal cord, either intravenously or intrathecally, resulted in long-term transgene expression in neurons of the spinal cord. Another field of interest are the neurological manifestations linked to HTLV-1 and their pathogenesis. He is currently in Jamaica trying to get a better understanding of the physiopathology of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). The current collaboration with the Gene Therapy Program of the University of Pennsylvania is focused on gene therapy approach in different neurodegenerative disorders, (more particularly in lysosomal diseases, i.e., mucopolysaccharidosis, MPS). Finally, He is involved in cell therapy using stem cells in different tissues (i.e., bone marrow stem cells, skeletal muscle, Central Nervous System). This approach emphasizes the interaction with regenerative medicine in a translational context. Intramarrow gene delivery of SV40-derived vectors downregulating CCR5 resulted in the reduction of excitotoxin-induced seizures and their harmful consequences. These results emphasize the role of CCR5 in the immune-mediated process underlying some forms of epilepsy. He is the author of more than 80 papers in peer-reviewed journals and more than 10 book chapters.
Dr. Zuoxing Zheng is Senior Associate Principal Scientist in Central Research at Kraft Foods Group, Inc. His primary function has been focused on identifying and developing novel and proprietary preservation technologies to improve food safety, quality and shelf life of various food and beverage products. Currently he is working on natural antimicrobial ingredients discovery and applications. Prior to joining Kraft Foods in 1999, he was Research Assistant at the University of Massachusetts from 1995 to 1999 and Assistant Professor at Tsinghua University from 1988 to 1995. He received his B.S. and M.S. degrees in Fermentation and Microbiology in China and Japan, and Ph.D. degree in Food Science from the University of Massachusetts. In more than two decades of his professional experience, he has authored dozens of journal papers, patent publications, book chapters and numerous conference presentations. He serves on the Food Biotechnology Editorial Board and is a reviewer for several scientific journals. He has received numerous awards from Kraft Foods, IFT and UNESCO.
Identify, discover and develop natural antimicrobial systems for food and beverage applications to improve food safety, quality and shelf life; Discover, improve and utilize beneficial microorganisms in food, agriculture and environmental applications; Produce value-added products from underutilized materials through microbial fermentation
Mohammed Masmudur Rahman received Ph.D. degree from the Department of Microbiology and Cell Biology at Indian Institute of Science (IISc), Bangalore, India, in 2004, where he studied virus-host interactions using baculovirus as a model and developed a baculovirus-based eukaryotic protein display system as a novel tool for vaccination. He then conducted postdoctoral research in the laboratory of Dr. Grant McFadden at the Roberts Research Institute, Ontario, Canada, where he studied poxvirus-encoded proteins that regulate host and cellular immune responses. The proteins are currently lead candidates for development as therapeutic agents by Viron Therapeutics Inc. He is currently Research Assistant Professorofthe Department of Molecular Genetics and Microbiology at the University of Florida. His research focuses on studying how poxviruses and DNA viruses modulate the cellular innate immune responses, in particular the inflammasome and NF-κB signaling pathways; molecular mechanism of viral cellular and host tropism;identification of novel host proteins and signaling pathways that modulate viral replication and tropism; virus-host protein-protein interactions; and Oncolytic virotherapy using poxviruses. He has published more than 50 peer-reviewed research and review articles in reputed journals.
Molecular virology; Host-virus interactions; Viral immunomodulatory proteins; Host anti-viral signaling pathways; Host immune response against viruses and regulation by viruses; Oncolytic virotherapy; Development of pathogen derived molecules as therapeutic agents for inflammatory diseases.
Star Metropolis Clinical Laboratories
United Arab Emirates
Dr. Ashok Rattan is a medical microbiologist by profession. He obtained his post graduate degree from Aligarh Muslim University, India and trained in MHH, Honnovar, Germany; CDC, Atlanta; NIH, Bethseda, USA and Dundee, Scotland. He has served as a faculty at the All India Institute of Medical Sciences, New Delhi during which time he published more than 100 research papers, guided over 40 students for their MD, MS or Ph D thesis and looked after the TB, STD and Hospital Infection Control Laboratories. He has also served as Laboratory Director of World Health Organization administered Caribbean Epidemiology Centre in Port of Spain. He has been associated with Fortis group of Hospitals and Religare SRL Diagnostic Laboratories. He has thirty international patents to his name. He is the author of National Book Trust sponsored book “Antibiotics in Laboratory Medicine” published by Churchill Livingstone.He is now with Arabian Healthcare charged with the responsibility of running reference laboratory network in the region.
Infectious Diseases; Antibacterial Agents; Molecular Biology; Vaccines; Immunology; Medical Microbiology.
Dr. Peter A Schad is currently the CSO of Digital Infuzion and PI of the Defense Threat Reduction Agency DTRA, Biosurveillance BSVE program. As Chief Scientific Officer (CSO) for Digital Infuzion, he assists the Chief Executive Officer in matters of strategy and scientific business direction. He also oversees the development of GeneBrain®, a software tool that models large volumes of Biological for monitoring, classification of samples, repository querying, biomarker identification, and the refinement and validation of hypothesis. He more than 20 years of experience in the areas of biotechnology including business development, infectious disease, oncology, genomics, and other “omics,” molecular biology, systems biology, bioinformatics, medical informatics, genetics, target validation, biomarker discovery, and in silico biology. He uniquely combines his biological and technical expertise to manage engineering and production of biological research and informatics programs. Prior to joining Digital Infuzion he was the Director of Molecular Epidemiology, Genomics, Environment and Health, (MEGEH) at RTI, managing a diverse group of “wet” lab scientists, population epidemiologists and computational scientists. He served as the Associate Director of Medical Informatics at The Cancer Institute of New Jersey (CINJ) providing strategic planning to clinical, medical informatics, and biomarker discovery in cancer. He provided strategy and thought management as the Health Informatics Coordinator for the National Cancer Institute (NCI) in the Division of Cancer Control and Population Sciences (DCCPS). He served as the Principal Investigator (PI) of the Genome Sequence Database (GSDB), which was one of four human genome databases at that time. At Alpha Gene, he developed the research and information technology (IT) strategy and developed a multi-disciplinary team infrastructure that classified a unique gene inventory into drug gable targets. He was also responsible for implementing a computational biology program as a discovery tool for genomics, proteomics, and biomarker validation. He has applied Advanced Mathematical Models (AMMs) to analyze and identify unique data sets within large and complex biological data. He has used AMMs to find a malignant signature within prostate cancer expression data, developed better silencing iRNA oligos, explored protein localization of unknown proteins, identified unknown pathways, and utilized AMMs to identify surrogate biomarkers for disease. Beginning his career, he worked on developing vaccines and pediatric vaccines for infectious disease at both Walter Reed Army Institute of Research (WRAIR) and at Praxis Biologics. He currently serves on several ad hoc National Institutes of Health (NIH) study sections for the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Dental and Craniofacial Research (NIDCR), and several Scientific Advisory Boards (SABs).
Using advanced mathematics and artificial intelligence with big data in the biological sciences to find predictors of disease, new associations not found using traditional statistical methods. Also using nontraditional data sources, such as social media, in detecting disease outbreaks/ biosuerviellance. Other research interests are in microbial identification in metagenomics and the human microbiomes.
Dr. Hulya Simsek is Associate Professor of Clinical Microbiology, and currently responsible for External Quality Assessment, training, on site evaluation, surveillence, and standardization of diagnostic methods atNational Tuberculosis Reference Laboratory (NRL). She has been working at NRL in Public Health Institution of Turkey since 2005. She gained her PhD from Gazi University in 2001. She had a research scholarfrom Turkish Ministry of Health for 6 months, and she had experienced on “new vaccination strategies by molecular techniques” and “investigation of novel drug targets for M. tuberculosis as genetically”at Mycobacteriology laboratory, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA. She obtained a research scholar from Ministry of Healthagain for three months. She has been as observer about "the Standardization of diagnostic methods in tuberculosis drug resistance"at Florida Department of Health, Bureau of Laboratories, Mycobacteriology Laboratory, Jacksonville, FL, USA. She joined a project “Development of PCR kit for diagnosis of Francisella tularensis”.
Microbiology; Laboratory diagnosis of Tuberculosis; External Quality Assessment
Satyajit Patra is Associate Professor and Chair of the Department of Biochemistry and Genetics at American International Medical University located in Saint Lucia, West Indies. He also currently serves as visiting faculty of Jayadev College of Pharmacy, Bhubaneswar, India. He received a B.Pharm degree from SRM University, Chennai in 1999, and a M.Pharm degree from Manipal University at Manipal. He received his Ph.D. in Cancer Molecular Biology from the Manipal University in 2008. From 2006 to 2009 he worked at Manipal University in Manipal, India eventually as an Assistant Professor. In 2009 he joined University of California at San Diego to pursue a postdoctoral fellowship. He joined Medical University of Americas at Nevis, West Indies as an Assistant Professor in the department of Biochemistry and Genetics in 2012. His research interests center on cellular genetic instability, accumulation of mutations, chromosome number instabilities and genetic alterations in tumors. He has explored the novel mutations in 3-methylcrotonyl-CoA carboxylase (MCC) a causing mechanism for causing methylcrotonylglycinuria. In addition he has made numerous contributions to marine source based drugs and their derivatives and understanding the mechanism of these natural drugs in cancer. He is recipient of prestigious Lady Tata Foundation fellowship, CSIR fellowship.
Repair of DNA double-strand breaks; Repair by homologous recombination; Mutation arrest in Cancer.
Farhang Babamahmoodi born in Iran 1950 and he studied medicine in Shahidbeheshti University of medical sciences and passed infectious diseases and tropical medicine course in Tehran University of medical sciences after that went to U.K (Glasgow) for more researches about Aids and immune deficiency problems. He was dean of Mazandaran University of medical sciences for 4 years and now he is the Chairman of infectious diseases department at Mazandaran University.
Muktikesh Dash obtained his M.B.B.S and M.D (Microbiology) degree from M.K.C.G Medical College and Hospital affiliated to Berhampur University, Odisha, India in the year 1997 and 2003 respectively. After completing his M.D, he joined as Lecturer and subsequently promoted to Assistant Professor in the Department of Microbiology, M.K.C.G Medical College and Hospital. He is currently full-time Associate Professor in the Department of Microbiology, S.C.B Medical College and Hospital, Utkal University, India. He has more than fourteen years of teaching, diagnostic and research experience in the field of Medical Microbiology. He has trained more than thousand medical officers and paramedical workers in HIV/AIDS, Vector borne diseases and transfusion transmitted infections. He has published more than 40 peer-reviewed research articles over his career on various topics related to HIV/AIDS, antimicrobial drug resistance and vector borne diseases. He has also served as Editorial board member and reviewer on a number of peer-reviewed national and international journals of repute.
HIV/AIDS, Antimicrobial drug resistance and Vector borne diseases
Dr. Godfred Antony Menezes is currently working in Hail University, Hail, Saudi Arabia as Assistant Professor & Scientist. Till 2014 April he was working as the Incharge/ Scientist of Central Research Laboratory (CRL) and also as an Assistant Professor of Microbiology at Sree Balaji Medical College & Hospital, Chennai, India. He has set up Central Research Laboratories in couple of Institutes. He has worked as Assistant Professor in the Department of Microbiology at SSR Medical College, Belle Rive Mauritius. I have also worked as a Scientist in the Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands. I was as a Junior Research Fellow and Research Scholar in the Institute of National Importance, JIPMER, Pondicherry, India. I have also worked as a short term research worker on Nanoscience at the renowned Indian Institute of Science (IISc, Bangalore, India). He has been working extensively on molecular characterization of Enterobacteriaceae members, particularly extended and expanded spectrum beta-lactamase producing bacteria and fluoroquinolone resistant bacteria. He has worked as faculty of several Medical Institutes and also a Paramedical Institute. He pursued his post-graduation in Medical Microbiology from Kasturba Medical College (KMC- MAHE University), Mangalore, India.
Pasquale Urbano, MD, PhD, now retired, was Full Professor of Microbiology at the Medical School of the University of Florence. His early research has dealt with picornaviruses, DNA oncogenic viruses, rotaviruses and several bacteria, of particular interest have been the epidemiologic aspects and the host-parasite relationships. He was awarded the Albert B. Sabin prize for virological research, and spent a year as research fellow at the Glasgow Institute of Virology. More recently he has engaged in the epistemology of medical science and in the ethics of research and of scientific communication. He adheres to the principles of evidence based medicine. As an expert in andragogy, he served as referee for the Italian program of continuing medical education. At present he is engaged as teacher and Coordinator in the Master for NBC Medicine jointly organized by the University of Florence and the Italian Army. Council member of the Italian association of medical microbiology (AMCLI), he was member of the American Society of Microbiology, of the European Society of Microbiology and Infectious Diseases, and of several other scientific societies.
Medical microbiology, Virology, Emerging infectious diseases, Epidemiology, Mycobacteriology, Biological weapons, Bioterrorism, Biometry and Medical statistics.
Dr. Maira Medellin-Pena obtained her medical degree in 2000 from the University of Ciudad Juarez in Mexico. Her interest in bacterial pathogenesis and food-borne zoonoses led her to pursue a career in Science and obtained the MSc in Microbiology and Molecular Biology in 2002 from the University of Chihuahua in Mexico. In 2007, she obtained her PhD from the Department of Food Sciences at the Canadian Research Institute for Food Safety at the University of Guelph with Dr. Mansel Griffiths working on the interference of quorum sensing regulation of virulence genes in Escherichia coli O157:H7 by molecules secreted by probiotic lactic acid bacteria. Dr. Medellin continued on as a postdoctoral fellow at the Department of Biochemistry and Biomedical Sciences at McMaster University in Canada with Dr. Justin Nodwell working on Bioinformatics analysis of whole genome sequences of bacterial pathogens in order to predict multidrug resistance genes; and functional genomics, developing an assay to predict the presence of unknown antimicrobial resistance genes in bacterial pathogens. In 2010, she joined Bioniche Life Sciences Inc. as Senior Microbiologist and Research and Development Laboratory Manager and after 3 years she was appointed Director of Chemistry, Manufacturing, and Controls in charge of several biologics development processes. Dr. Medellin joined NovaVive Inc. in July, 2014 as the Vice-President of Research and Development, a role in which she continues to work on bacterial pathogenesis, infection immunology and towards the goal of lessening the misuse of antibiotics in food animals.
Bacterial Pathogenesis; Immunology; Bioinformatics; Foodborne Zoonoses; Vaccines; Mechanisms of Antibiotic Resistance; and Emerging Pathogens.
Dr. Testerman received her Ph.D. in Microbiology and Immunology from the University of Colorado Health Sciences Center, where she studied Salmonella stress response and pathogenicity. She received postdoctoral training at the University of Maryland-Baltimore and the University of South Alabama before becoming a faculty member at LSU Health Sciences Center-Shreveport. She joined the faculty of the University Of South Carolina School Of Medicine in 2014. She has made significant contributions to defining Helicobacter pylori nutritional requirements, physiology, and iron acquisition mechanisms. The Testerman laboratory discovered that H. pylori preferentially binds apo-transferrin and apo-lactoferrin, which is highly unusual for a bacterial pathogen and further discovered two novel H. pylori adhesins that influence the development of gastric inflammation. She is investigating the mechanisms through which these adhesins modulate inflammation and the role of inflammation in various extra gastric diseases. In a separate line of investigation, the Testerman laboratory is studying the roles of H. pylori and other bacterial species in colorectal and appendiceal cancers. A collaborative research project revealed that H. pylori and other bacteria are present within a rare peritoneal cancer, pseudomyxoma peritonei (PMP). She has isolated several unusual bacterial species from peritoneal tumors, including one representing a new genus, and seeks to determine whether these species contribute to tumor development or growth.
Dr. Albert Ruff received his PhD from The Johns Hopkins University School of Medicine, Department of Pharmacology and Molecular Biology. He completed his postdoctoral research at the US Army Medical Research Institute of Infectious Disease (USAMRIID) as part of the National Research Council Postdoctoral Research Associate Program. He ultimately became a principal investigator at USAMRIID and worked in the field of Ebola virus vaccine development. Following his tenure at USAMRIID, he served as a biological warfare and biological terrorism analyst for Science Applications International Corporation and then as an assistant professor of biology at Lee University where he taught courses such as microbiology, virology, cell biology and immunology. He is currently a program advisor and principal investigator at the US Army Medical Research Institute of Chemical Defense (USAMRICD). His research is primarily focused on vesicants such as sulfur mustard and toxic industrial chemicals, which can also induce skin or eye injury. The goal of his research is to understand the cellular and molecular responses to these agents. His laboratory has developed both in vivo and in vitro models to study these injuries and is applying techniques such as high throughput siRNA screening and high content analysis to understand mechanisms of injury in the in vitro models. His work on high content analysis of cellular injury has led to a role in the USAMRICD Adsorption Distribution Metabolism Excretion and Toxicity Center of Excellence in which his laboratory is performing high content screening of drugs in development for liver injury potential.
Inflammation; High Content Analysis; Inhibitory RNA; Molecular and Cellular Mechanisms; Hepatotoxicity